Pay in 4 interest-free payments of $5.59 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
MONDAY, June 8, 2026 (HealthDay News) -- Glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with reduced risks for thromboembolic events, emergency department use, and mortality among adults with obesity and autoimmune diseases (AIDs), according to a study published online June 6 in the Journal of the American Heart Association to coincide with the annual meeting of the American Diabetes Association, held from June 5 to 8 in New Orleans.Hao Dai, Ph.D., from the Indiana University School of Medicine in Indianapolis, and colleagues conducted a retrospective cohort study, which emulated a target trial using 2014 to 2024 electronic health record data to examine the association between GLP-1 RA use and major adverse cardiovascular and thromboembolic event risk among adults with obesity and AID
In contrast, glucagon-like peptide-1 receptor (GLP-1R) agonists have emerged as an obesity treatment, offering significant weight loss and meaningful improvements in associated health outcomes
Presented for research literature review only TAKATORI K et al
-1775582746855.png&w=3840&q=75)
& Adewole, D
& Kalsbeek, A
The most common side effects are upset stomach, nausea, and diarrhea
